TP-0184
Phase 1/2Terminated 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anemia in Myelodysplastic Syndromes
Conditions
Anemia in Myelodysplastic Syndromes
Trial Timeline
Dec 28, 2020 → Apr 27, 2021
NCT ID
NCT04623996About TP-0184
TP-0184 is a phase 1/2 stage product being developed by Sumitomo Pharma for Anemia in Myelodysplastic Syndromes. The current trial status is terminated. This product is registered under clinical trial identifier NCT04623996. Target conditions include Anemia in Myelodysplastic Syndromes.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04623996 | Phase 1/2 | Terminated |
| NCT03429218 | Phase 1 | Completed |
Competing Products
20 competing products in Anemia in Myelodysplastic Syndromes
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aranesp® | Amgen | Approved | 84 |
| KER-047 | Keros Therapeutics | Phase 2 | 44 |
| LY2787106 | Eli Lilly | Phase 1 | 33 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| epoetin beta + placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| recombinant human erythropoietin + recombinant human erythropoietin placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| recombinant human erythropoietin + recombinant human erythropoietin | Chugai Pharmaceutical | Phase 3 | 77 |
| darbepoetin alfa | Amgen | Phase 3 | 76 |
| Prasugrel | Daiichi Sankyo | Phase 1 | 33 |
| Prasugrel + Placebo | Daiichi Sankyo | Phase 2 | 52 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| Roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 77 |
| Alefacept | Astellas Pharma | Phase 1 | 33 |
| Roxadustat | Astellas Pharma | Phase 2 | 52 |
| roxadustat | Astellas Pharma | Phase 1 | 33 |
| Roxadustat + Placebo | Astellas Pharma | Phase 3 | 77 |
| Roxadustat | Astellas Pharma | Pre-clinical | 23 |
| Roxadustat + Epoetin Alfa | Astellas Pharma | Phase 3 | 77 |
| roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 77 |